Paul B. Manning - 24 Jul 2023 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
24 Jul 2023
Net transactions value
+$1,004,000
Form type
4
Filing time
24 Jul 2023, 18:47:54 UTC
Previous filing
29 Jun 2023
Next filing
16 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Purchase $1,004,000 +200,000 +2.6% $5.02 7,851,128 24 Jul 2023 Direct F1, F2, F3
holding VRCA Common Stock 6,000,000 24 Jul 2023 By PBM 2022 Grantor Retained Annuity Trust
holding VRCA Common Stock 1,481,719 24 Jul 2023 See footnote F4
holding VRCA Common Stock 256,634 24 Jul 2023 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.75 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 Reflects the Reporting Person's contribution of shares into the PBM 2022 Grantor Retained Annuity Trust. This transfer of shares constitutes a change in the form of beneficial ownership and was exempt from reporting.
F3 The shares are held by Mr. Manning jointly with his spouse.
F4 The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
F5 The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.